Venture&Growth
Location
Heidelberg, Germany
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
mtm laboratories manufactures and commercializes in-vitro diagnostic tests for the analysis of cervical cancer. Worldwide, cervical cancer is the second most common cancer in women. mtm’s CINtec® technology detects a specific cellular biomarker (p16INK4a) and offers the potential for highly specific and accurate diagnosis of early-stage cervical cancer, even if it is without symptoms.
Since Gilde invested in mtm laboratories, the German company has clinically validated its diagnostic products and more than doubled its sales. mtm laboratories was acquired by Roche in 2011.
More mtm laboratories news
Study of CINtec® PLUS in the management of Pap negative but HPV positive women published
mtm laboratories Extends Series C Financing Round by EUR 7 Million ($9.7 Million)
MTM Laboratories – p16 Immuno-cytochemistry shows superior clinical performance to HPV testing
mtm’s CINtec® PLUS, delivers new solution to manage Pap negative but HPV positive women
mtm laboratories Announces the European Launch of CINtec(R) PLUS
MTM LABORATORIES – CINtec® p16 Histology test increases accuracy in diagnosing
GILDE HEALTHCARE II invests in mtm laboratories AG
Venture&Growth
GT Medical Technologies
GT Medical Technologies (GT) is a commercial stage, US-based medical device company that specializes in developing innovative products for the treatment of brain tumors. GT has created a product called GammaTile Therapy, which is an implantable radiation therapy for the
Venture&Growth
Inari Medical
US MedTech company focused on removal of blood clots to treat pulmonary embolism or deep vein thrombosis.
Venture&Growth
CatalYm
CatalYm is a clinical-stage immuno-oncology company improving the outcomes of existing checkpoint inhibitor therapies in difficult-to-treat cancer types. The company has identified GDF-15 as a key cancer therapy resistance mechanism and is developing it as a safe and efficacious immune
